Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Immune Design (IMDZ) to finish Phase 1b trial of CMB305 (Sequentially Administered LV305 and G305) in Patients with Cancer Expressing NY-ESO-1 in early 2018

Source Link:: https://www.clinicaltrials.gov/ct2/show/NCT02387125?term=cmb305&rank=1

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

IMDZ

50%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Evaluate the safety and tolerability, immunogenicity, and preliminary clinical efficacy of CMB305 in patients with locally advanced, relapsed or metastatic solid cancers, whose tumors express NY-ESO-1

http://www.immunedes...

Additional Relevant Details CMB305 is a prime-boost approach in which LV305 is dosed sequentially with G305 to induce a synergistic anti-tumor cytotoxic T lymphocyte (CTL) response. CMB305 may also generate memory CTLs, and therefore long-term immune surveillance, as well as enhance other immune anti-tumor mechanisms.

http://immunedesign....

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Mar 12, 2018

Occurred Source:

http://ir.immunedesign.com/news-releases/news-release-details/immune-design-reports-data-update-lead-immunotherapy-programs

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Phase 1b Trial, Cmb305, Lv305, G305, Ny-eso, Ny-eso-1 Cancers, Sarcoma, Melanoma, Ovarian Cancer, Non-small Cell Lung Cancer